Tara Rheault
Overview
Explore the profile of Tara Rheault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dransfield M, Marchetti N, Kalhan R, Reyner D, Dixon A, Rheault T, et al.
Chron Respir Dis
. 2025 Jan;
22:14799731251314874.
PMID: 39854278
Background: The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis...
2.
Sciurba F, Christenson S, Rheault T, Bengtsson T, Rickard K, Barjaktarevic I
Chest
. 2024 Aug;
167(2):425-435.
PMID: 39197510
Background: Exacerbations in COPD can be life-threatening and can lead to irreversible declines in lung function and quality of life. Medications that reduce exacerbation burden are an unmet need, because...
3.
Mahler D, Bhatt S, Rheault T, Reyner D, Bengtsson T, Dixon A, et al.
Expert Rev Respir Med
. 2024 Aug;
18(8):645-654.
PMID: 39106052
Background: Dyspnea is a critical component of chronic obstructive pulmonary disease (COPD). We report the effect of ensifentrine, a novel PDE3/PDE4 inhibitor, on dyspnea using pooled data from the Phase...
4.
Anzueto A, Barjaktarevic I, Siler T, Rheault T, Bengtsson T, Rickard K, et al.
Am J Respir Crit Care Med
. 2023 Nov;
209(2):226-228.
PMID: 37939377
No abstract available.
5.
Donohue J, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K
Int J Chron Obstruct Pulmon Dis
. 2023 Aug;
18:1611-1622.
PMID: 37533771
Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in...
6.
Anzueto A, Barjaktarevic I, Siler T, Rheault T, Bengtsson T, Rickard K, et al.
Am J Respir Crit Care Med
. 2023 Jun;
208(4):406-416.
PMID: 37364283
Clinicaltrials: gov and EudraCT (ENHANCE-1, www. Clinicaltrials: gov identifier NCT04535986, EudraCT identifier 2020-002086-34; ENHANCE-2, www. Clinicaltrials: gov identifier NCT04542057, EudraCT identifier 2020-002069-32).
7.
Ferguson G, Kerwin E, Rheault T, Bengtsson T, Rickard K
Int J Chron Obstruct Pulmon Dis
. 2021 Apr;
16:1137-1148.
PMID: 33911859
Purpose: Ensifentrine is an inhaled dual inhibitor of phosphodiesterase (PDE) 3 and 4 that has shown bronchodilatory effects and symptom improvement in clinical studies in patients with chronic obstructive pulmonary...
8.
Watz H, Rickard K, Rheault T, Bengtsson T, Singh D
Int J Chron Obstruct Pulmon Dis
. 2020 Sep;
15:2199-2206.
PMID: 32982212
Introduction: Ensifentrine is an inhaled first-in-class dual inhibitor of phosphodiesterase (PDE) 3 and 4. In a four-week randomized, double-blind, placebo-controlled, parallel-group study in patients with chronic obstructive pulmonary disease (COPD),...
9.
Rheault T, Khindri S, Vahdati-Bolouri M, Church A, Fahy W
ERJ Open Res
. 2016 Oct;
2(2).
PMID: 27730198
This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease. This was a 12-week, multicentre,...
10.
Sibi M, Zimmerman J, Rheault T
Angew Chem Int Ed Engl
. 2003 Oct;
42(37):4521-3.
PMID: 14520755
No abstract available.